CJC-1295: what it is, how it's logged

The central characteristic of CJC-1295 is its division into two functionally separate variants: one with a Drug Affinity Complex (DAC) and one without. This structural difference is not a minor detail; it fundamentally alters the peptide's half-life from several minutes to approximately one week. Consequently, any plan to study or document this compound must begin by identifying which of the two distinct versions is being used, as their administration schedules diverge completely. Failure to distinguish between the 'with DAC' and 'no-DAC' forms is the most significant source of error when logging its use.

The no-DAC version is frequently referred to in research literature as Modified GRF (1-29) or Mod GRF 1-29. It is a tetra-substituted analog of Growth Hormone Releasing Hormone (GHRH) with a very short duration of action, similar to the peptide sermorelin. Because of its transient nature, it is almost universally studied in conjunction with a ghrelin mimetic like ipamorelin to produce a synergistic effect. In contrast, the DAC variant's long-acting profile allows for much less frequent administration, fundamentally changing how protocols are structured and documented.

The historical context for CJC-1295 originates with the Canadian biotechnology firm ConjuChem, which designed the compound in the early 2000s as part of a larger strategic platform. Its core innovation was not the base GHRH analog itself (a tetrasubstituted 29-amino-acid peptide), but the inclusion of its proprietary Drug Affinity Complex (DAC) technology. This platform was engineered with the broad objective of extending the circulating half-life of various therapeutic peptides and proteins, addressing a common challenge in peptide-based drug development. The primary goal was to decrease dosing frequency by enabling the molecule to bind covalently to serum albumin, a long-lived and abundant protein in the bloodstream. Thus, CJC-1295 with DAC should be understood as one specific application of a broader pharmaceutical research strategy focused on modifying the pharmacokinetic properties of biologics.

Both forms of CJC-1295 are analogs of GHRH and function by binding to and stimulating the Growth Hormone Releasing Hormone receptor (GHRHr) in the anterior pituitary gland. Stimulation of this receptor initiates the downstream cascade that results in the synthesis and release of growth hormone. The core peptide sequence responsible for this action is the first 29 amino acids of GHRH, which is what the 'no-DAC' variant (Mod GRF 1-29) comprises, with four specific amino acid substitutions to inhibit degradation.

The key divergence occurs with the addition of the Drug Affinity Complex. The DAC version includes a lysine residue linked to maleimidopropionic acid, which forms a covalent bond with the protein serum albumin after administration. This binding protects the peptide from enzymatic degradation by dipeptidyl peptidase-4 (DPP-IV) and dramatically reduces its clearance rate by the kidneys. This novel mechanism effectively turns circulating albumin into a temporary carrier for the peptide, extending its biological half-life from mere minutes to a span of 6-8 days.

The mechanism responsible for the extended duration of CJC-1295 with DAC involves a precise and stable chemical modification. The DAC component is a specialized maleimidopropyl group that is chemically reactive towards thiol groups, such as those found on cysteine residues within proteins. In the bloodstream, this group selectively forms a strong, covalent bond with a specific cysteine residue (Cys34) of circulating albumin. Once this bond is formed, the large albumin protein effectively acts as a carrier vehicle, sterically shielding the much smaller GHRH analog from rapid enzymatic degradation and renal clearance. This process of 'albumin-hitching' is what transforms the peptide's kinetic profile, increasing its half-life from minutes to several days, a central concept researchers study when they observe its long-term activity.

The process to calculate the volume for a specific dose depends on the concentration of the reconstituted solution. For a numeric example, if a 2 mg vial of lyophilized CJC-1295 powder is reconstituted with 2 mL of bacteriostatic water, the resulting solution has a concentration of 1,000 mcg per mL. To draw an example dose of 100 mcg for the no-DAC variant, one would calculate the required volume as 0.1 mL, which corresponds to 10 units on a U-100 type insulin syringe.

The choice of diluent volume can be adjusted to suit the specific variant being studied. For the small, frequent 100 mcg doses of no-DAC CJC-1295, using a larger volume of diluent like 2 mL or even 3 mL can make the small dose volume easier to measure with precision. For the much larger, infrequent doses of the DAC version (e.g., 500-2000 mcg), a smaller volume of diluent, such as 1 mL, might be chosen to keep the total injection volume manageable.

A critical preliminary step before any reconstitution or use is to correctly identify and document the specific variant of CJC-1295 being handled. Vials sourced for research are typically labeled distinctly as either 'CJC-1295' (often implying the no-DAC variant, also known as Mod GRF 1-29) or explicitly as 'CJC-1295 w/ DAC' or 'CJC-1295 with DAC'. Because the administration schedule observed in research can differ by a factor of seven or more between the two, confirming this identity from the supplier documentation and vial label is essential for accurate record-keeping. Documenting the specific variant in a tracking log establishes the foundational data point upon which all subsequent scheduling and analysis depend, preventing a fundamental error in the dataset from the very beginning.

Before it is reconstituted, the freeze-dried powder should be stored at refrigerated temperatures. After the peptide is dissolved with a diluent, the resulting solution's chemical structure is maintained by continuous refrigeration. Researchers typically plan to complete their study of a single reconstituted vial within a 30-day timeframe.

Protocols developed for the no-DAC version (Mod GRF 1-29) are defined by frequent administration due to its rapid clearance. Dosing schedules often involve one to three administrations per day to create distinct pulses of GH release, with a common example dose being 100 mcg per instance, leading to a schedule of 7 or more administrations per week. This variant is almost always paired with a Ghrelin Receptor Agonist (a GHRP like ipamorelin) in the same syringe to amplify the pituitary's response through a secondary receptor pathway.

Conversely, protocols for CJC-1295 with DAC are structured around its long half-life, requiring much less frequent administration. A typical research schedule might involve a single administration once or twice per week, with doses that are correspondingly larger to maintain elevated GH and IGF-1 levels over the interval. The choice between these two protocols is absolute; applying a daily dosing schedule intended for the no-DAC version to the long-acting DAC version would be a significant protocol error, and vice versa.

Divergent study designs directly reflect the profound pharmacokinetic differences between the two CJC-1295 variants. Research protocols involving the no-DAC version, sometimes referred to as Mod GRF 1-29, typically schedule administrations on a daily or even multi-daily basis to account for its very short half-life and maintain stable levels for observation. As a numeric example for personal tracking, a 2 mg vial reconstituted with 2 mL would yield a concentration of 1,000 mcg/mL; a 100 mcg illustrative dose is 0.1 mL or 10 units on a U-100 syringe, logged on a daily cadence (no-DAC variant). In stark contrast, studies observing the DAC variant plan for a much lower administration frequency, often weekly, to align with its long-lasting presence in circulation.

When studying the no-DAC variant, which is commonly co-administered with ipamorelin, the most critical tracking detail is to record each peptide as a separate log entry. Even if both substances are drawn into and administered from a single syringe, they must be documented as two distinct events in a digital log. Failure to do this will cause the per-vial inventory count to drift within weeks, showing one vial as empty while the other is still physically present, which complicates future planning and corrupts the integrity of historical data.

For precise and auditable personal data logging, it is crucial to establish a specific entry for the subject peptide variant at the start of any documentation cycle. Modern tracking applications allow for custom fields or detailed notes where users should consistently record 'with DAC' or 'no-DAC' for their CJC-1295 supply. This single piece of metadata governs the entire planned schedule and the ultimate interpretation of any observed results over time. When reviewing logs weeks or months later, this variant information is indispensable for preventing misinterpretation of data, as the expected compound exposure from a daily versus a weekly administration schedule is fundamentally different. This simple logging practice ensures that all downstream analysis is based on a correct premise about the substance being monitored.